ライフサイエンスコーパス: competitive binding

1 nds to receptors in trigeminal neurons using competitive binding.

2 complex formation prompted investigation of competitive binding.

3 ence data suggest based on a model of direct competitive binding.

4 e analyzed for contributions to interspecies competitive binding.

5 cyclin A-Cdk2 from inhibition by p27 through competitive binding.

6 duce the effects of CD30-targeting agents by competitive binding.

7 tyrosine phosphorylation of WBP2 and TAZ/YAP competitive binding.

8 locus of the antibody and the percentage of competitive binding.

9 ally act to displace interacting proteins by competitive binding.

10 placement of ATMND from 38-GC as a result of competitive binding.

11 NA cleavage ability of CRISPR-Cas12a and the competitive binding activities of aTFs for small molecul

12 oughout the human genome, often resulting in competitive binding activity at nearby or overlapping ci

13 We found that the competitive binding affinities of the small GTPase for S

14 Through a competitive binding affinity assay and a number of physi

15 nm, lambda(em)=400 nm) of c-SAHA due to its competitive binding against other HDAC inhibitors, and s

16 se were all present could be modeled using a competitive binding algorithm.

17 Results from fluorescence spectroscopic and competitive binding analyses indicated that the specific

18 Competitive binding analyses revealed that alpha-FhbB Ab

19 Competitive binding analysis and mutagenesis reveals a u

20 Using competitive binding analysis with nonlabeled competitor

21 Competitive binding and [(35)S]GTPgammaS functional assa

22 re the diversity of the internal sites using competitive binding and DNase I protection assays and sh

23 aluated for activity at the H(4) receptor in competitive binding and functional assays.

24 Competitive binding and internalization experiments were

25 Competitive binding and kinetic studies with exosite mut

26 Further competitive binding and mutational analysis showed that

27 toluene below its saturation level revealed competitive binding and resulted in an average increase

28 ions that impact gene expression by enabling competitive binding and switching between transcription

29 Competitive binding and transcription assays demonstrate

30 measured in a fluorescence polarization (FP) competitive binding assay and are active in human cancer

31 osis proteins (XIAP) with a Ki of 61 nM in a competitive binding assay and directly antagonizes the X

32 erivatives 6-11 were tested in vitro using a competitive binding assay and ex vivo using a rat aortic

33 Liquiritigenin showed ERbeta selectivity in competitive binding assay and isoliquiritigenin was equi

34 d to have >50% inhibition at 100 nM in a CB1 competitive binding assay and were further characterized

35 alutamide, mifepristone, DHT, and R1881 in a competitive binding assay as compared to wild-type AR LB

36 s (Ki values) for inhibitors in the FP-based competitive binding assay conditions, and accordingly, a

37 The competitive binding assay demonstrated that both SarAr-S

38 Analysis of 2 by flow cytometry and competitive binding assay demonstrates that immunoconjug

39 Using a newly developed competitive binding assay dependent upon the reassembly

40 The Fe3O4 NP-based competitive binding assay detected ATP and pyrophosphate

41 cells and was inactive in a [(3)H]astemizole competitive binding assay for hERG liability screening.

42 A competitive binding assay gave a dissociation constant o

43 A displacement competitive binding assay indicates that DOTA-IO-RGD con

44 results obtained indicated that the FP-based competitive binding assay performs correctly as designed

45 Important effects of surface chemistry and competitive binding assay protocol on the sensitivity of

46 ose concentrations when implemented within a competitive binding assay system.

47 ted structural analogues were evaluated in a competitive binding assay to breast cancer cell lysate a

48 In addition, a competitive binding assay to detect cardiac Troponin I (

49 nat)Ga-/(nat)Lu-PSMA I&T was determined in a competitive binding assay using LNCaP cells.

50 The unlabeled peptides were evaluated in a competitive binding assay using PC-3 prostate cancer cel

51 Methods: A competitive binding assay was performed using Chinese ha

52 Methods: A competitive binding assay was performed using Chinese ha

53 4h, and 4s are similar, as confirmed by the competitive binding assay where the ability of the ligan

54 In a competitive binding assay with a Eu-labeled probe based

55 idin/4'-hydroxyazobenzene-2-carboxylic acid) competitive binding assay, and fluorescence correlation

56 ally were tested experimentally in an MCH-R1 competitive binding assay, and six novel chemotypes as l

57 assay, EC(50) = 20 nM) and binding affinity (competitive binding assay, K(i) = 25 nM).

58 In a fluorescence competitive binding assay, the selective ligand binding

59 the applied nonradioactive 96-well plate TTR competitive binding assay.

60 finity for the Hsp90 ATP binding site in the competitive binding assay.

61 ARgamma-ligand binding domain in a PPARgamma competitive binding assay.

62 s for PSMA were determined by screening in a competitive binding assay.

63 ion of the small molecule as well as using a competitive binding assay.

64 lpha(v)beta5 was evaluated in a heterologous competitive binding assay.

65 ity in a [(3)H]histamine radiolabeled ligand competitive binding assay.

66 led NDP-alpha-MSH and was used to optimize a competitive binding assay.

67 PSMA inhibition constants were evaluated by competitive binding assay.

68 with reported values measured by an indirect competitive binding assay.

69 es' biorecognition capabilities for use in a competitive binding assay.

70 unterparts was determined in LNCaP cells via competitive binding assays (IC(50)) and dual-tracer radi

71 compounds were synthesized and evaluated in competitive binding assays and an androgen receptor tran

72 By performing competitive binding assays and expressing truncated NS1

73 Using competitive binding assays and molecular modeling, we es

74 These findings are supported by results of competitive binding assays and the similarity of the x-r

75 nists are 10-50-fold selective for ERbeta in competitive binding assays and up to 60-fold selective i

76 ide analogues of M6G and C6G was examined by competitive binding assays at mu, delta, and kappa opioi

77 Competitive binding assays based on the lectin Concanava

78 f label-free real-time optical biosensors in competitive binding assays by epitope binning a panel of

79 ar alpha-syn in vivo, but we show that SIL23 competitive binding assays can be used to screen additio

80 Competitive binding assays confirm binding to specific t

81 T20/C37 competitive binding assays confirmed that T20 interacts

82 Finally, based on these observations, competitive binding assays for these three small analyte

83 Competitive binding assays in the lateral septum showed

84 However, gel shift and competitive binding assays indicated that the JRL domain

85 In vitro competitive binding assays revealed a preferred binding

86 Competitive binding assays revealed that clone 47 also s

87 Consistent with these results, competitive binding assays revealed the following relati

88 Competitive binding assays strongly suggest that EGCG do

89 We present evidence from both direct and competitive binding assays that no significant recogniti

90 RNA immunoprecipitation (RIP) combined with competitive binding assays to identify novel primary tar

91 Competitive binding assays using a novel whole virus-cel

92 determined with high accuracy by two simple competitive binding assays using a scandium complex deri

93 Competitive binding assays using intact radiolabeled myc

94 Competitive binding assays using radiolabeled omega-atra

95 Competitive binding assays utilizing concanavalin A (Con

96 Saturation and competitive binding assays with B16F10 melanoma cells de

97 three other species, are designed as surface-competitive binding assays with fluorescence readouts.

98 This ligand was used in competitive binding assays with results comparable to th

99 These labeled ligands were used in competitive binding assays with results comparable to th

100 plasmon resonance, fluorescence microscopy, competitive binding assays, and animal studies.

101 In competitive binding assays, CC-5079 competes with [(3)H]

102 gh the use of novel chimeric HA proteins and competitive binding assays, that sequential infection of

103 ions and validated these predictions through competitive binding assays.

104 ma1 receptors (sigma1Rs) were determined via competitive binding assays.

105 receptor endocytosis assays and heterologous competitive binding assays.

106 h also indicated a mechanism consistent with competitive binding at mAChRs.

107 er and repressor activities, possibly due to competitive binding at similar DNA binding sites.

108 ic cucurbit[n]uril congener toward guests by competitive binding at the ureidyl C horizontal lineO po

109 or to hydrogel systems or other matrixes for competitive-binding-based system, as they provide free m

110 the accurate characterization of binding and competitive binding behavior in biological systems.

111 e mutually exclusive, confirming their known competitive binding behavior.

112 3, and, in vitro, we document reversible and competitive binding between a wild-type purified Plin1 1

113 Competitive binding between Ca(2+) and Mg(2+) to PIP2 is

114 ference in behavior can be attributed to the competitive binding between isocitrate and alphaKG, whic

115 d for detecting OSCS in heparin based on the competitive binding between OSCS and the adenosine-repea

116 or the mom-2 3'UTR reporter is determined by competitive binding between positive- and negative-actin

117 The assay is based on the competitive binding between PrP and a peptide-fluorophor

118 ignals that may be associated with potential competitive binding between Sox2 and Tcf3.

119 sor is fully reversible and specific through competitive binding between the dendrimer and glucose wi

120 he rate of reaction is controlled by initial competitive binding between the furylcarbinol and nitrog

121 ant was tested against osanetant, indicating competitive binding between the two antagonists as well.

122 Furthermore, we find evidence of competitive binding between the two divalent ion species

123 for which binding to eIF4G is RNA dependent, competitive binding by 100K protein is RNA independent.

124 Competitive binding by JQ1 displaces the BRD4 fusion onc

125 l-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, d

126 We conclude that competitive binding can be a pragmatic approach for impr

127 crystallographic approaches and radiolabeled competitive binding-capacity assays, we report here how

128 rgy transfer based glucose sensor, wherein a competitive binding (CB) assay is encapsulated into poly

129 The dominant nonlinearity in our model is competitive binding (CB): Only one odorant molecule can

130 al assay configuration, the sensitivity of a competitive binding chemistry using ConA can be appropri

131 er DNA promoted more efficient binding under competitive binding conditions and was functionally impo

132 creen assay for a 384-well plate format in a competitive binding configuration for discovery of new i

133 Thus, the developed AlphaScreen assay in a competitive binding configuration offers several advanta

134 Competitive binding ELISA, native electrophoresis follow

135 Competitive binding ELISAs with N-terminal mutants and a

136 ause the presence of the cavitand leads to a competitive binding equilibrium in which the stronger bi

137 We couple dissociation to a competitive binding event so that dissociation can be dr

138 In a competitive binding experiment, EpCAM aptamer generated

139 Molecular docking and TR-FRET GR competitive binding experiments demonstrated that ASI co

140 er (NET), and dopamine transporter (DAT)) in competitive binding experiments in vitro using cloned hu

141 Competitive binding experiments indicated that the radio

142 Here, de novo Rosetta modeling and competitive binding experiments show that the acidic tip

143 Competitive binding experiments showed that Mmp-8 and Mm

144 The results of competitive binding experiments suggest that a common ad

145 Competitive binding experiments suggest that Zn and Cd s

146 Competitive binding experiments using a series of ligand

147 Competitive binding experiments using unlabeled and 125I

148 Catch and release competitive binding experiments were done by NMR for the

149 The detection of vancomycin was achieved in competitive binding experiments with a horseradish perox

150 Next, we evaluated assay performance by competitive binding experiments with a series of known l

151 (AdV5) were observed at those VIPs, even in competitive binding experiments with minute virus of mic

152 The assay was tested in competitive binding experiments with substrates and prod

153 -permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement w

154 Neutralizing activity, competitive binding groups, and epitope specificity of S

155 This competitive binding has largely hindered the application

156 s were all shown to inhibit PCNA function by competitive binding in both human and S. pombe cells as

157 ity was confirmed to be mediated through ATP competitive binding in the ATP binding pocket of the kin

158 s slides, and fumonisin B1 was detected in a competitive binding inhibition assay using the antifumon

159 HEp-2 cell binding assays and in MAb and LRP competitive binding inhibition assays and based on the r

160 cant implications on the in vitro testing of competitive binding inhibitors and determines optimal in

161 Competitive binding inhibitors based on multivalent nano

162 functionally unique and did not result from competitive binding interactions.

163 at the resistance of the LacI-DNA complex to competitive binding is a function of both the operator s

164 s, followed by analysis with the widely used competitive binding kinetics theory developed by Motulsk

165 This demonstrates the potential of utilizing competitive binding kinetics to analyze multivalent inte

166 r potency in three in vitro assays including competitive binding, Matrigel invasion and Galpha(i) cyc

167 A novel FRET competitive binding measurement developed to quantitate

168 e demonstrate that DHP has a unique two-site competitive binding mechanism in which the internal and

169 stranded DNA-binding site, suggesting that a competitive binding mechanism may regulate the formation

170 viously, we and others discovered that via a competitive binding mechanism, the proteins WTX (AMER1),

171 eptor (AR)-FOXA1 and AR-HOXB13 complexes and competitive binding mechanisms.

172 apid kinetic, surface plasmon resonance, and competitive binding methods.

173 d displacement in a manner consistent with a competitive binding mode at the orthosteric site by TBPB

174 of their inhibitory kinetics revealed a non-competitive binding mode, with an IC50 value against ACE

175 ization of 74 with human CD73 demonstrates a competitive binding mode.

176 tures demonstrated a canonical acetyl-lysine competitive binding mode.

177 illustrate that this provides support for a competitive binding model and adds new insight into a di

178 Consistent with a competitive binding model for TFAM repression of HSP2, t

179 We have explored a competitive binding model using specific mutations in th

180 domain, encompasses the cases treated by the competitive binding model, and provides a somewhat bette

181 dentified via systematic deviations from the competitive-binding model.

182 ive exact analytical expressions for general competitive binding models which can also explain a comm

183 igh-throughput screening method based on the competitive binding of a lumazine synthase inhibitor and

184 roach for antipsychotic drug screening where competitive binding of a novel APD and DA to a dopamine

185 Conversely, and very importantly, the competitive binding of a target DNA or protein with SWNT

186 A cantilever device based on competitive binding of an immobilized receptor to immobi

187 pertoires can be reached via the dynamics of competitive binding of antigens by receptors and selecti

188 tide conjugate was developed on the basis of competitive binding of AuNP-LHP and LH toward anti-LH.

189 e pituitary, through a combined mechanism of competitive binding of both ActRII and ALK4 by each subu

190 The competitive binding of calcium and the mobile segment of

191 te that chemokine cooperativity is caused by competitive binding of chemokines to GAGs.

192 The immunoassay scheme consists of the competitive binding of cocaine-specific antibodies to th

193 Force-jump kinetic investigations suggested competitive binding of cPDS and BG4 to the TERRA GQ.

194 cts of DOC on Cu uptake, possibly due to the competitive binding of Cu between the dissolved phase an

195 Upon the addition of analyte solutions, competitive binding of cyanotoxin to the specific aptame

196 We now show that D/N interference involves competitive binding of D/N Vif variants to the transcrip

197 S-based multiplexing arises in balancing the competitive binding of different signal generating dyes

198 A sensitive assay for competitive binding of dinucleosome substrates revealed

199 I-[MePhe7]NKB as the radioligand, indicating competitive binding of either antagonist with regard to

200 Competitive binding of ethanolamine and fluorescently la

201 ore, blockade of HepII-mediated signaling by competitive binding of fibulin-1 or tenascin-C represent

202 f the inactivation rates, suggesting partial competitive binding of hirudin-(54-65)(SO(3)(-)) and HCI

203 dulate JunD mRNA degradation by altering the competitive binding of HuR and AUF1 to the JunD 3'-UTR.

204 The 11-state mechanism accounts for competitive binding of inhibitors and activation by diff

205 our results do not support a model in which competitive binding of misfolded proteins causes dissoci

206 n of the BiP-ATF6 complex is a result of the competitive binding of misfolded proteins generated duri

207 The approach allows the competitive binding of multiple DNA sequences to the giv

208 s of the selectivity filter in which to test competitive binding of Na(+) These experiments disclosed

209 (c) Inhibition by excess olefin is caused by competitive binding of olefin and aryl starting material

210 Here we show that the competitive binding of pentose monophosphate inhibitors

211 on of carrageenan is based on the concept of competitive binding of positively charged MB to the nega

212 spholipase C (PLC) beta activity, due to the competitive binding of RACK1, PI3K gamma, and PLC beta t

213 Competitive binding of radio-labeled proteins to western

214 calization of GFP-Kif17 to the cilia tip and competitive binding of RP2 and Arl3 with Kif17 complexes

215 NAs (ceRNAs), which regulate target genes by competitive binding of shared microRNAs.

216 Competitive binding of small guanosine triphosphatases t

217 These results suggest that competitive binding of Sp family proteins regulate betaM

218 Specifically, the competitive binding of streptavidin and goat anti-biotin

219 In this design, competitive binding of target to the aptamer causes the

220 The two complexes are formed by the competitive binding of Tec1 and Dig2 with Ste12, as Tec1

221 Disrupting AEG-1-Akt2 interaction by competitive binding of the Akt2-PH domain led to reduced

222 dynamics simulations revealed a Vroman-like competitive binding of the amphiphiles for the graphene

223 ca shell microparticles to create a site for competitive binding of the antibodies (Abs).

224 TM, the fluorescence was restored due to the competitive binding of the aptamer to GO.

225 A model that partitions this trend into the competitive binding of the co-salt anion to the hydropho

226 xin 4 complexes are further regulated by the competitive binding of the double C2 domain protein Doc2

227 Competitive binding of the human monoclonal antibody (mA

228 Mutual competitive binding of the mAbs indicated the presence o

229 todextrin utilization genes are regulated by competitive binding of the maltose repressor MalR and ca

230 concentrations, which most likely is due to competitive binding of the noncomplementary nucleotide t

231 The results corroborate our proposal that competitive binding of the transported ions to two (or m

232 nical signaling pathway and results from the competitive binding of the two sugars to hexose transpor

233 external proton concentration, indicative of competitive binding of these two ligands to extracellula

234 ing complex immunoprecipitation demonstrates competitive binding of TRADD and RIP to TNFR1, whereas T

235 , thus H3-tail demethylation; (ii) block the competitive binding of transcription factors; and (iii)

236 A mathematical model based on competitive binding of two antibodies for up to four ant

237 nd P-body composition and miscibility, while competitive binding of unconnected proteins disengages n

238 With this view, we investigate the effect of competitive binding on the dynamics of CaM binding partn

239 inhibitor binding by SPR without the use of competitive binding or antibodies.

240 Affinity Reagents (MegaSTAR) to identify non-competitive binding pairs of recombinant affinity reagen

241 dulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR in HepG2 cells.

242 pad" for increasing the duration of the key competitive binding reaction and uses silver amplificati

243 ), which results in systematic shifts in the competitive binding response curve.

244 ryptophans in LDLR for both ligands, and the competitive binding results showed an involvement of the

245 phenol A, and acrolein) in human serum via a competitive binding scheme.

246 (2+), Cd(2+), and Hg(2+) revealed a mutually competitive binding site common to three metal ions and

247 and relative energies for hydration of these competitive binding sites at 133 K are obtained from the

248 hatic C-H donors are observed to function as competitive binding sites in solution and suggest that s

249 5.9 +/- 2.4 microM), but a novel, two-phased competitive binding strategy was necessary to ascertain

250 Competitive binding studied by isothermal titration calo

251 Competitive binding studies are consistent with a specif

252 Competitive binding studies demonstrated that soluble he

253 urther validated by binding, inhibition, and competitive binding studies of CvGal1 and ABH-specific m

254 Competitive binding studies of mixtures of the Fab-activ

255 Surprisingly, competitive binding studies reveal that Co(NH(3))(6)(3+)

256 Furthermore, competitive binding studies reveal that these chemically

257 Competitive binding studies showed a high affinity of th

258 ptide adopts the PPII conformation, however, competitive binding studies showed an order of magnitude

259 Competitive binding studies suggested that Ec-CDT and Hd

260 Competitive binding studies with a thrombin-specific chr

261 Competitive binding studies with excess trastuzumab befo

262 exhibited IC(50) values lower than 20 nM in competitive binding studies with GPR30-expressing human

263 Competitive binding studies with heparin pentasaccharide

264 Competitive binding studies with low-affinity heparin an

265 No product inhibition is observed, and competitive binding studies with nitro-containing additi

266 Competitive binding studies with P450eryF preloaded with

267 eries of peptides derived from beta-actin in competitive binding studies, we show that the domain nec

268 additionally failed to bind A3G, ruling out competitive binding to A3G or the E3 ubiquitin ligase co

269 We propose that competitive binding to alpha2 by the ubiquitylation mach

270 Competitive binding to eIFiso4G was also observed betwee

271 pressing HT1080hFAP cells were used to study competitive binding to FAP, cellular uptake, internaliza

272 information within a thermodynamic model of competitive binding to jointly learn a holistic view of

273 eIF4B and eIFiso4G exhibited competitive binding to PABP, supporting the overlapping

274 35Ab1 and the aforementioned proteins: 1) No competitive binding to rootworm BBMV was observed for co

275 combined with unlabeled Cry34Ab1, and 2) No competitive binding to rootworm BBMV was observed for un

276 dvantage to S. gordonii over S. sanguinis in competitive binding to sHA.

277 host defense against bacterial infection by competitive binding to target glycolipid molecules.

278 the cortisol level is detected based on its competitive binding to the aptamer by following signal f

279 Competitive binding to the Hsp90 N-terminal domain was o

280 are similar and have coevolved to facilitate competitive binding to the IL-1 receptor.

281 ufu and Spop oppose each other through their competitive binding to the N- and C-terminal regions of

282 w that these compounds display high affinity competitive binding to the PPARgamma-LBD (EC(50) of 215

283 fering with cytoadhesion of infected RBCs by competitive binding to these receptors in vitro and redu

284 Competitive binding to VEGF between VEGFR and bevacizuma

285 petitive inhibitor of transport but displays competitive binding towards selective serotonin reuptake

286 p and apply a physical model of TF-chromatin competitive binding using chemical reaction rate theory

287 ligands to RXRalpha was demonstrated through competitive binding using ultrafiltration LC-MS/MS (liqu

288 nd only Cu(+) co-migrated with ZiaA(N) after competitive binding versus Zn(2+).

289 Competitive binding was verified using the same soil wit

290 ucted, and seven VHH clones were selected by competitive binding with 3-PBA.

291 Competitive binding with [(3)H]spiroperidol was used to

292 ined by change in capacitance after allowing competitive binding with CRP and complementary RNA (cRNA

293 verely compromised by background signals and competitive binding with extrinsic probes.

294 ta suggest that RRP1 is involved not only in competitive binding with fibrillarin to C1QBP on 90S but

295 and their cognate HiBiT-tagged GPCRs through competitive binding with fluorescent tracers.

296 y equilibrium binding of SC-(1-325) to ProT, competitive binding with native ProT, and SC domain inte

297 ptor was identified by (+)-[(3)H]pentazocine competitive binding with nonradioactive [(127)I]IAF, it

298 Utf1 buffers bivalent gene expression by competitive binding with polycomb repressive complex 2 a

299 s of AAV2 transduction influenced by Notch1, competitive binding with soluble heparin and Notch1 anti

300 f IL12p70, IL12p40, and IL12(p40)2 and their competitive binding with the IL-12 receptor are essentia